Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment

International Journal of Oncology

Volumn 34, Issue 3, 2009, Pages 743-755

  Freeburg, Elizabeth M ^a   Goyeneche, Alicia A ^a   Telleria, Carlos M ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Cell death; Cisplatin; Mifepristone; Ovarian cancer; Repopulation

Indexed keywords

CISPLATIN; DNA; HISTONE H3; MIFEPRISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL COUNT; CELL CULTURE; CELL CYCLE; CELL POPULATION; CELL VIABILITY; CLONOGENESIS; COLONY FORMING CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DNA SYNTHESIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL DEATH; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; MIFEPRISTONE; OVARIAN NEOPLASMS;

EID: 63549138551     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000200     Document Type: Article

References (50)

1. DiSaia PJ and Bloss JD: Treatment of ovarian cancer: new strategies. Gynecol Oncol 90: S24-S32, 2003.
2. Martin VR: Ovarian cancer: an overview of treatment options. Clin J Oncol Nurs 11: 201-207, 2007.
3. Naora H and Montell DJ: Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5: 355-366, 2005.
4. Ozols RF: Challenges for chemotherapy in ovarian cancer. Ann Oncol 17 (Suppl. 5): 181-187, 2006.
5. Bukowski RM, Ozols RF and Markman M: The management of recurrent ovarian cancer. Semin Oncol 34: S1-S15, 2007.
6. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C and Perez JM: Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 7: 3-18, 2007.
7. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
8. Kim JJ and Tannock IF: Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: 516-525, 2005.
9. Davis AJ and Tannock JF: Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 1: 86-93, 2000.
10. Brade AM and Tannock IF: Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol 24: 1020-1022, 2006.
11. Licun W and Tannock IF: Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. Clin Cancer Res 9: 4614-4618, 2003.
12. Wu L and Tannock IF: Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clin Cancer Res 11: 8195-8200, 2005.
13. Wu L, Birle DC and Tannock IF: Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65: 2825-2831, 2005.
14. Philibert D, Moguilewsky M, Mary I, Lecaque D, Tournemine C, Secchi J and Deraedt R: Pharmacological profile of RU486 in animals. In: The Antiprogesterone Steroid RU486 and Human Fertility Control. Baulieu EE and Segal SJ (eds). Plenum Press, NY, 1985.
15. Fedele L and Berlanda N: Emerging drugs for endometriosis. Expert Opin Emerg Drugs 9: 167-177, 2004.
16. Steinauer J, Pritts EA, Jackson R and Jacoby AF: Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 103: 1331-1336, 2004.
17. Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F and Schoenlein PV: Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFß1. Int J Oncol 23: 369-380, 2003.
18. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH and Lee EY: Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314: 1467-1470, 2006.
19. Schneider CC, Gibb RK, Taylor DD, Wan T and Gercel-Taylor C: Inhibition of endometrial cancer cell lines by mifepristone (RU 486). J Soc Gynecol Investig 5: 334-338, 1998.
20. El Etreby MF, Liang Y, Johnson MH and Lewis RW: Antitumor activity of mifepristone in the human LNCaP, LNCaP-c4, and LNCaP-c4-2 prostate cancer models in nude mice. Prostate 42: 99-106, 2000.
21. Li DQ, Wang ZB, Bai J, Zhao J, Wang Y, Hu K and Du YH: Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro. World J Gastroenterol 10: 2628-2631, 2004.
22. Rose FV and Barnea ER: Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 12: 999-1003, 1996.
23. Goyeneche AA, Caron RW and Telleria CM: Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 13: 3370-3379, 2007.
24. Coley HM: Development of drug-resistant models. Methods Mol Med 88: 267-273, 2004.
25. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M and Howell SB: Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62: 6559-6565, 2002.
26. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278: 19245-19256, 2003.
27. Ormerod MG, O'Neill C, Robertson D, Kelland LR and Harrap KR: Cis-diamminedichloroplatinum(ii)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37: 463-471, 1996.
28. Melichar B, Hu W, Patenia R, Melicharova K, Gallardo ST and Freedman R: rINF-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. J Transl Med 1: 5, 2003.
29. Scovassi AI and Poirier GG: Poly(ADP-ribosylation) and apoptosis. Mol Cell Biochem 199: 125-137, 1999.
30. Mack PC, Gandara DR, Lau AH, Lara PN Jr, Edelman MJ and Gumerlock PH: Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol 51: 337-348, 2003.
31. Hendzel MJ, Wei Y, Mancini MA, van Hooser A, Ranalli T, Brinkley BR, Bazett-Jones DP and Allis CD: Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106: 348-360, 1997.
32. Taylor WR: FACS-based detection of phosphorylated histone H3 for the quantitation of mitotic cells. Methods Mol Biol 281: 293-299, 2004.
33. Mansouri A, Zhang Q, Ridgway LD, Tian L and Claret FX: Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res 13: 399-404, 2003.
34. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, Vanderhyden B, Faught W, Fung MF, Senterman M, Korneluk RG and Tsang BK: Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142: 370-380, 2001.
35. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Saito M, Kawagoe J, Takahashi K, Yada-Hashimoto N, Sakata M, Motoyama T, Kurachi H, Tasaka K and Murata Y: Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279: 23477-23485, 2004.
36. Rasola A, Anguissola S, Ferrero N, Gramaglia D, Maffe A, Maggiora P, Comoglio PM and Di Renzo MF: Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res 64: 1744-1750, 2004.
37. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE and Tsang BK: Chemoresistance in human ovarian cancer: The role of apoptotic regulators. Reprod Biol Endocrinol 1: 66, 2003.
38. Vassileva V, Allen CJ and Piquette-Miller M: Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther 7: 630-637, 2008.
39. Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, Hartmann JT, Bokemeyer C and Mayer F: Cellcycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 29: 471-479, 2006.
40. Kvinlaug BT and Huntly BJ: Targeting cancer stem cells. Expert Opin Ther Targets 11: 915-927, 2007.
41. Sorenson CM, Barry MA and Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755, 1990.
42. Vakifahmetoglu H, Olsson M and Zhivotovsky B: Death through a tragedy: mitotic catastrophe. Cell Death Differ 15: 1153-1162, 2008.
43. Vakifahmetoglu H, Olsson M, Tamm C, Heidari N, Orrenius S and Zhivotovsky B: DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ 15: 555-566, 2008.
44. Vermeulen K, van Bockstaele DR and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149, 2003.
45. Deans AJ, Khanna KK, McNees CJ, Mercurio C, Heierhorst J and McArthur GA: Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res 66: 8219-8226, 2006.
46. Berton TR, Mitchell DL, Guo R and Johnson DG: Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation. Oncogene 24: 2449-2460, 2005.
47. Helleday T, Petermann E, Lundin C, Hodgson B and Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204, 2008.
48. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
49. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F and Reed E: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645-652, 2000.
50. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63: 1311-1316, 2003.